These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 18693916)

  • 1. Assessing the impact of HL7/FDA Structured Product Label (SPL) content for medication knowledge management.
    Schadow G
    AMIA Annu Symp Proc; 2007 Oct; 2007():646-50. PubMed ID: 18693916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HL7 Structured Product Labeling - electronic prescribing information for provider order entry decision support.
    Schadow G
    AMIA Annu Symp Proc; 2005; 2005():1108. PubMed ID: 16779395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profiling structured product labeling with NDF-RT and RxNorm.
    Zhu Q; Jiang G; Chute CG
    J Biomed Semantics; 2012 Dec; 3(1):16. PubMed ID: 23256517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structured product labeling improves detection of drug-intolerance issues.
    Schadow G
    J Am Med Inform Assoc; 2009; 16(2):211-9. PubMed ID: 18952933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracting drug indication information from structured product labels using natural language processing.
    Fung KW; Jao CS; Demner-Fushman D
    J Am Med Inform Assoc; 2013 May; 20(3):482-8. PubMed ID: 23475786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of Food and Drug Administration--approved medications for unlabeled (off-label) uses. The legal and ethical implications.
    Torres A
    Arch Dermatol; 1994 Jan; 130(1):32-6. PubMed ID: 8285737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WLF and the two-click rule: the First Amendment inequity of the Food and Drug Administration's regulation of off-label drug use information on the Internet.
    Ward SM
    Food Drug Law J; 2001; 56(1):41-56. PubMed ID: 11942350
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk management strategies in the Physicians' Desk Reference product labels for pregnancy category X drugs.
    Uhl K; Kennedy DL; Kweder SL
    Drug Saf; 2002; 25(12):885-92. PubMed ID: 12241129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 2015 US Food and Drug Administration Pregnancy and Lactation Labeling Rule.
    Brucker MC; King TL
    J Midwifery Womens Health; 2017 May; 62(3):308-316. PubMed ID: 28556499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using RxNorm and NDF-RT to classify medication data extracted from electronic health records: experiences from the Rochester Epidemiology Project.
    Pathak J; Murphy SP; Willaert BN; Kremers HM; Yawn BP; Rocca WA; Chute CG
    AMIA Annu Symp Proc; 2011; 2011():1089-98. PubMed ID: 22195170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA cracks down on labeling, initiates trial result reporting.
    Osborne R; Waltz E
    Nat Biotechnol; 2008 Nov; 26(11):1203-4. PubMed ID: 18997742
    [No Abstract]   [Full Text] [Related]  

  • 12. Analyzing categorical information in two publicly available drug terminologies: RxNorm and NDF-RT.
    Pathak J; Chute CG
    J Am Med Inform Assoc; 2010; 17(4):432-9. PubMed ID: 20595311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exceptions or alternatives to labeling requirements for products held by the Strategic National Stockpile. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2012 Feb; 77(24):5696-9. PubMed ID: 22359804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing Drug-Disease Associations in Clinical Practice Guideline Recommendations and Drug Product Label Indications.
    Leung TI; Dumontier M
    Stud Health Technol Inform; 2015; 216():1039. PubMed ID: 26262338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International Coherence of Pediatric Drug Labeling for Drug Safety: Comparison of Approved Labels in Korea and the United States.
    Song YK; Han N; Burckart GJ; Oh JM
    Clin Pharmacol Ther; 2020 Mar; 107(3):530-540. PubMed ID: 31544241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 17. A dataset of 200 structured product labels annotated for adverse drug reactions.
    Demner-Fushman D; Shooshan SE; Rodriguez L; Aronson AR; Lang F; Rogers W; Roberts K; Tonning J
    Sci Data; 2018 Jan; 5():180001. PubMed ID: 29381145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory experts debate FDA's authority.
    Young D
    Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA resurrects, finalizes labeling rule.
    Traynor K
    Am J Health Syst Pharm; 2006 Mar; 63(5):398, 400. PubMed ID: 16484509
    [No Abstract]   [Full Text] [Related]  

  • 20. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH
    Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.